JP2005516956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516956A5 JP2005516956A5 JP2003554685A JP2003554685A JP2005516956A5 JP 2005516956 A5 JP2005516956 A5 JP 2005516956A5 JP 2003554685 A JP2003554685 A JP 2003554685A JP 2003554685 A JP2003554685 A JP 2003554685A JP 2005516956 A5 JP2005516956 A5 JP 2005516956A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- branched
- linear
- alkyl group
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- -1 methylenedioxy group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000005332 alkyl sulfoxy group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002253 anti-ischaemic effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000009251 neurologic dysfunction Effects 0.000 claims 1
- 208000015015 neurological dysfunction Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 210000004789 organ system Anatomy 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105406A HUP0105406A3 (en) | 2001-12-21 | 2001-12-21 | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| PCT/HU2002/000144 WO2003053969A1 (en) | 2001-12-21 | 2002-12-17 | Imidazoquinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005516956A JP2005516956A (ja) | 2005-06-09 |
| JP2005516956A5 true JP2005516956A5 (https=) | 2005-12-22 |
| JP4530663B2 JP4530663B2 (ja) | 2010-08-25 |
Family
ID=47711504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554685A Expired - Fee Related JP4530663B2 (ja) | 2001-12-21 | 2002-12-17 | イミダゾキノリン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7176213B2 (https=) |
| EP (1) | EP1456205A1 (https=) |
| JP (1) | JP4530663B2 (https=) |
| KR (2) | KR100725298B1 (https=) |
| CN (1) | CN1307174C (https=) |
| AU (1) | AU2002353241B2 (https=) |
| BR (1) | BR0215272A (https=) |
| CA (1) | CA2470067C (https=) |
| EA (1) | EA007226B1 (https=) |
| HR (1) | HRP20040671A2 (https=) |
| HU (1) | HUP0105406A3 (https=) |
| IL (2) | IL162443A0 (https=) |
| IS (1) | IS7317A (https=) |
| MA (1) | MA27240A1 (https=) |
| MX (1) | MXPA04006115A (https=) |
| NO (1) | NO329743B1 (https=) |
| NZ (1) | NZ534015A (https=) |
| PL (1) | PL370761A1 (https=) |
| RS (1) | RS56104A (https=) |
| TN (1) | TNSN04105A1 (https=) |
| UA (1) | UA78745C2 (https=) |
| WO (1) | WO2003053969A1 (https=) |
| ZA (1) | ZA200404807B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1430032A2 (en) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
| AU2006216822A1 (en) * | 2005-02-22 | 2006-08-31 | Daniel Rachmilewitz | Methods of treating gastrointestinal inflammation |
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| US8357132B1 (en) | 2009-10-21 | 2013-01-22 | Lekweuwa Agatha N | Urine capturing assembly |
| DK2950649T3 (da) | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| PE20181366A1 (es) | 2015-08-03 | 2018-08-27 | Bristol Myers Squibb Co | Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
| GB1596652A (en) | 1977-01-20 | 1981-08-26 | Roussel Lab Ltd | Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives |
| IL59104A (en) | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
| GR76063B (https=) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
-
2001
- 2001-12-21 HU HU0105406A patent/HUP0105406A3/hu unknown
-
2002
- 2002-12-17 WO PCT/HU2002/000144 patent/WO2003053969A1/en not_active Ceased
- 2002-12-17 MX MXPA04006115A patent/MXPA04006115A/es active IP Right Grant
- 2002-12-17 KR KR1020047009788A patent/KR100725298B1/ko not_active Expired - Fee Related
- 2002-12-17 CA CA2470067A patent/CA2470067C/en not_active Expired - Fee Related
- 2002-12-17 EP EP02788261A patent/EP1456205A1/en not_active Withdrawn
- 2002-12-17 AU AU2002353241A patent/AU2002353241B2/en not_active Ceased
- 2002-12-17 NZ NZ534015A patent/NZ534015A/en not_active IP Right Cessation
- 2002-12-17 KR KR1020077004953A patent/KR20070034136A/ko not_active Ceased
- 2002-12-17 CN CNB02825645XA patent/CN1307174C/zh not_active Expired - Fee Related
- 2002-12-17 BR BR0215272-0A patent/BR0215272A/pt not_active IP Right Cessation
- 2002-12-17 JP JP2003554685A patent/JP4530663B2/ja not_active Expired - Fee Related
- 2002-12-17 HR HR20040671A patent/HRP20040671A2/xx not_active Application Discontinuation
- 2002-12-17 RS YU56104A patent/RS56104A/sr unknown
- 2002-12-17 PL PL02370761A patent/PL370761A1/xx not_active Application Discontinuation
- 2002-12-17 EA EA200400847A patent/EA007226B1/ru not_active IP Right Cessation
- 2002-12-17 UA UA20040706065A patent/UA78745C2/uk unknown
- 2002-12-17 US US10/499,251 patent/US7176213B2/en not_active Expired - Fee Related
- 2002-12-17 IL IL16244302A patent/IL162443A0/xx unknown
-
2004
- 2004-06-07 MA MA27725A patent/MA27240A1/fr unknown
- 2004-06-08 TN TNP2004000105A patent/TNSN04105A1/en unknown
- 2004-06-10 IL IL162443A patent/IL162443A/en not_active IP Right Cessation
- 2004-06-16 IS IS7317A patent/IS7317A/is unknown
- 2004-06-17 ZA ZA200404807A patent/ZA200404807B/xx unknown
- 2004-07-20 NO NO20043117A patent/NO329743B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6061857B2 (ja) | モルヒナン誘導体 | |
| JP7787063B2 (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| CN105492423B (zh) | 四氢环戊并吡咯衍生物及用于制备其的方法 | |
| JP4890723B2 (ja) | ＴＮＦαインヒビターとして有用なクマリン誘導体 | |
| JP4846665B2 (ja) | ピラゾロ［１，５−ａ］ピリミジン化合物 | |
| KR101921404B1 (ko) | 신규 2치환 1,2,4-트리아진 화합물 | |
| BG100727A (bg) | Тетрациклени производни, метод за получаване и приложение | |
| JP2005505618A5 (https=) | ||
| WO1997047622A1 (en) | Cytokine production inhibitors, triazepine compounds, and intermediates thereof | |
| JP6158193B2 (ja) | 新規レニン阻害薬 | |
| JP7239246B2 (ja) | アンドロゲン受容体調節因子及びグルココルチコイド受容体調節因子としての新規アナログ | |
| JP2006515572A5 (https=) | ||
| RU2009149518A (ru) | Триазоло[1, 5-а]хинолины в качестве лигандов рецептора аденозина а3 | |
| JP2005516956A5 (https=) | ||
| JP2004536074A5 (https=) | ||
| JP4533148B2 (ja) | アデノシンａ３受容体リガンドとしてのイミダゾキノリン誘導体 | |
| JPH0565288A (ja) | 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物 | |
| JPS6267031A (ja) | 胃腸ぜん動の調節物質としてのα↓２−アドレナリン受容体拮抗物質 | |
| JP2005507390A5 (https=) | ||
| JPWO2003004497A1 (ja) | 新規複素環化合物 | |
| EP0874849A1 (en) | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives | |
| JPWO1997020845A1 (ja) | ピロロアゼピン誘導体 | |
| JP2012211085A (ja) | ヘッジホッグシグナル阻害剤 | |
| KR20220097388A (ko) | 헤테로시클릭 아미드계 화합물, 이의 약학적으로 허용 가능한 염 및 이의 제조 방법 및 용도 | |
| JP7688449B2 (ja) | ピリジン縮合環系化合物とその製造方法、中間体、組成物及び使用 |